<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227835</url>
  </required_header>
  <id_info>
    <org_study_id>METC 2017-0058</org_study_id>
    <nct_id>NCT03227835</nct_id>
  </id_info>
  <brief_title>Contrast-Induced Nephropathy After Revision of the Prophylaxis Threshold</brief_title>
  <acronym>CINART</acronym>
  <official_title>Contrast-Induced Nephropathy After Revision of the Prophylaxis Threshold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After administration of intravascular iodinated contrast media Contrast-Induced Nephropathy
      (CIN), also known as Contrast-Induced Acute Kidney Injury (CIAKI), may occur. CIN/CI-AKI is
      associated with increased risk of dialysis and mortality. No treatment exists for CIN/CI-AKI,
      therefore the focus lies on prevention. Clinical practice guidelines for the prevention of
      CIN/CI-AKI exist and are implemented in most hospitals. Generally, intravascular volume
      expansion with normal saline is recommended as prophylaxis.

      Earlier this year the results of the AMACING study were published in The Lancet
      (NL47173.068.14/METC 14-2-006; Clinical Trials.gov NCT02106234;
      http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30057-0/fulltext). These
      results show that for the greater part (&gt;90%) of patients considered to be at risk of
      CIN/CI-AKI by the guidelines, withholding prophylaxis is non-inferior to giving standard
      intravenous prophylactic hydration in the prevention of CIN/CI-AKI. Furthermore, the standard
      prophylactic hydration confers some risk (5.5% complications of intravenous hydration were
      recorded in the AMACING study).

      As a result the clinical protocol in the MUMC+ has been adapted, and patients with an eGFR
      &gt;29mL/min/1.73m2 no longer receive intravenous prophylactic hydration before or after
      procedures with intravascular iodinated contrast material administration.

      CINART is a one year prospective observational study with the aim to evaluate the
      consequences of the protocol change for renal function, incidence of CIN/CI-AKI, and dialysis
      and mortality.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-Induced Nephropathy</measure>
    <time_frame>2-6 days post contrast administration</time_frame>
    <description>&gt;25% or &gt;44umol/L increase in serum creatinine from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-month renal function</measure>
    <time_frame>26-35 days post-contrast</time_frame>
    <description>change in serum creatinine / eGFR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-month dialysis/mortality</measure>
    <time_frame>26-35 days post-contrast</time_frame>
    <description>incidences of dialysis and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean (change in) serum creatinine</measure>
    <time_frame>2-6, 26-35 days post-contrast</time_frame>
    <description>mean (change in) serum creatinine in micromol per litre</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Contrast-induced Nephropathy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intravascular iodinated contrast material administration</intervention_name>
    <description>Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR &gt;29mL/min/1.73m2</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at risk of CIN/CIAKI according to the guidelines and an eGFR between
        30-59mL/min/1.73m2, who are referred for an elective procedure with intravascular iodinated
        contrast administration at the MUMC+ after the protocol change i.e. the threshold for
        prophylactic intravenous hydration has been lowered to eGFR&lt;30mL/min/1.73m2.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  referred for an elective procedure with intravascular iodinated contrast
             administration at Maastricht University Medical Centre

          -  eGFR30-44mL/min/1.73m2 OR eGFR45-59mL/min/1.73m2 + DM OR eGFR45-59mL/min/1.73m2 + &gt;1
             risk factor (&gt;age &gt;75 years, anaemia, cardiovascular disease, prescribed NSAID or
             Diuretic medication) OR multiple myeloma/lymphoplasmacytic lymphoma with small chain
             proteinuria.

        Exclusion Criteria:

          -  eGFR&lt;30mL/min/1.73m2

          -  Dialysis/renal replacement therapy

          -  emergency procedure

          -  intensive care patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JE Wildberger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Estelle Claire Nijssen</last_name>
    <phone>+31433875908</phone>
    <email>estelle.nijssen@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JE Wildberger</last_name>
    <phone>+31(0)43-3876912</phone>
    <email>j.wildberger@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Zuid-Limburg</state>
        <zip>6202AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle Claire Nijssen, MSc</last_name>
      <phone>+31 (043)-38 72 649</phone>
      <email>estelle.nijssen@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Joachim E Wildberger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, Ommen VV, Wildberger JE. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017 Apr 1;389(10076):1312-1322. doi: 10.1016/S0140-6736(17)30057-0. Epub 2017 Feb 21.</citation>
    <PMID>28233565</PMID>
  </reference>
  <reference>
    <citation>Centraal BegeleidingsOrgaan (CBO). CBO richtlijnen contrast. 2007 Available from: www.cbo.nl/product/richtlijnen/folder20021023121843/rl_jodium_2007</citation>
  </reference>
  <reference>
    <citation>Veligheids Management Systeem. VMS veiligheidsprogramma. Voorkomen van nierinsufficiÃ«ntie bij intravasculair gebruik van jodiumhoudende contrastmiddelen. September 2009. 2009 [cited; Available from: http:/www.vmszorg.nl/10- Themas/Nierinsufficientie/Praktijkgids-Nierinsufficientie</citation>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contrast-induced nephropathy</keyword>
  <keyword>contrast-induced acute kidney injury</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>intravenous hydration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

